Evidence map›Paper›PMID 35583654›Full record

ReviewAdvances in experimental medicine and biology2022

Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.

Dora Rolo, Ana Tavares, Nádia Vital, Maria João Silva, Henriqueta Louro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. State of the Art of Genomic Technology in Toxicology: A Review.International journal of molecular sciences · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dora RoloDepartment of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal. dora.rolo@insa.min-saude.pt.
Ana TavaresDepartment of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.
Nádia VitalDepartment of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.
Maria João SilvaDepartment of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.ORCID https://orcid.org/0000-0002-6060-0716
Henriqueta LouroDepartment of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.ORCID https://orcid.org/0000-0001-9744-7332
National Institute of Health Dr. Ricardo Jorge · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials (NMs) have important and useful applications in chemical industry, electronics, pharmaceuticals, food and others. Their rapid proliferation presents a dilemma to regulators regarding hazard identification and increased concerns for public health.The Adverse Outcome Pathways (AOPs) are innovative central elements of a toxicological knowledge framework, developed for supporting chemical risk assessment based on mechanistic reasoning. AOPs describe a sequence of causally linked events at different levels of biological organisation, triggered by exposure to a stressor (like chemicals or NMs) leading to an adverse health effect in humans or wildlife. The integrative analysis of the cellular and molecular mechanisms of nanotoxicity towards the identification of connected adverse outcomes drives a sequential line - an AOP landscape definition. Each defined AOP is available for crossing data, linking known and unknown landscapes, reducing the reliance on animal studies, associated costs and ethical issues. NMs have unique properties, with specific associated toxicological challenges, which may represent unknown AOP landscapes.In this chapter, an overview of AOPs as important novel strategic tools in nanotoxicology is presented, highlighting the current applications in hazard identification and human health risk assessment.

Indexed as

Adverse Outcome PathwaysDrug-Related Side Effects and Adverse ReactionsNanostructuresAnimalsRisk AssessmentAdverse outcomeNanomaterialsNanotoxicologyRisk assessment

Identifiers

PMID35583654
OpenAlexW4285112769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.